Enliven Therapeutics (ELVN) Operating Income Growth (5y) (2024 - 2026)
Enliven Therapeutics (ELVN) Operating Income Growth (5y) (2024 - 2026) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Oculis Holding AG | 66,801.52 Bn | 66,801.23 Bn | - |
| 2 | Nanobiotix | 1,935.05 Bn | 1,934.98 Bn | - |
| 3 | Akari Therapeutics | 1,021.31 Bn | 1,021.31 Bn | - |
| 4 | BeOne Medicines | 467.89 Bn | 463.10 Bn | 1.35 Bn |
| 5 | Vertex Pharmaceuticals | 122.95 Bn | 115.70 Bn | 2.59 Bn |
| 6 | Regeneron Pharmaceuticals | 70.19 Bn | 61.44 Bn | 3.31 Bn |
| 7 | Belite Bio | 63.46 Bn | 63.46 Bn | - |
| 8 | Argenx Se | 55.64 Bn | 50.45 Bn | 1.41 Bn |
| 9 | Alnylam Pharmaceuticals | 37.67 Bn | 34.66 Bn | 959.66 Mn |
| 10 | Enliven Therapeutics | 3.43 Bn | 2.98 Bn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -22.03% |
| Dec 31, 2025 | -24.31% |
| Sep 30, 2025 | -14.97% |
| Jun 30, 2025 | -22.64% |
| Mar 31, 2025 | -33.94% |
| Dec 31, 2024 | -29.16% |
| Sep 30, 2024 | -31.51% |
| Jun 30, 2024 | -34.66% |
| Mar 31, 2024 | -44.02% |